Epigenome-wide association study of alcohol use disorder in five brain regions
Open accessPublished version of a preprint
Abstract
Alcohol use disorder (AUD) is closely linked to the brain regions forming the neurocircuitry of addiction. Postmortem human brain tissue enables the direct study of the molecular pathomechanisms of AUD. This study aims to identify these mechanisms by examining differential DNA-methylation between cases with severe AUD ( n = 53) and controls ( n = 58) using a brain-region-specific approach, in which sample sizes ranged between 46 and 94. Samples of the anterior cingulate cortex (ACC), Brodmann Area 9 (BA9), caudate nucleus (CN), ventral striatum (VS), and putamen (PUT) were investigated. DNA-methylation levels were determined using the Illumina HumanMethylationEPIC Beadchip. Epigenome-wide association analyses were carried out to identify differentially methylated CpG-sites and regions between cases and controls in each brain region. Weighted correlation network analysis (WGCNA), gene-set, and GWAS-enrichment analyses were performed. Two differentially methylated CpG-sites were associated with AUD in the CN, and 18 in VS ( q < 0.05). No epigenome-wide significant CpG-sites were found in BA9, ACC, or PUT. Differentially methylated regions associated with AUD case-/control status ( q < 0.05) were found in the CN ( n = 6), VS ( n = 18), and ACC ( n = 1). In the VS, the WGCNA-module showing the strongest association with AUD was enriched for immune-related pathways. This study is the first to analyze methylation differences between AUD cases and controls in multiple brain regions and consists of the largest sample to date. Several novel CpG-sites and regions implicated in AUD were identified, providing a first basis to explore epigenetic correlates of AUD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Human studies to assess epigenetic modifications have been limited to measures made in blood cells or in post-mortem brain.
“Human studies to assess epigenetic modifications have been lim ited to measures made in blood cells or in post- mortem brain 115,116 .”
From Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention (2023) · cites this paper as [115]
The Materials and methods (Samples; page unavailable) describe methylation measurements in human postmortem brain, and the Discussion (page unavailable) compares such studies with EWAS in peripheral blood. The paper does not establish the broader claim that human studies of epigenetic modifications have been limited to those two sample types. (LLM, conf=0.82)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 68 · Cited by 36
- Authors
- Zillich, L., Frank, J., Streit, F., Friske, M. M., Foo, J. C., Sirignano, L., Heilmann-Heimbach, S., Dukal, H., Degenhardt, F., Hoffmann, P., Hansson, A. C., Nöthen, M. M., Rietschel, M., Spanagel, R., & Witt, S. H.
- Affiliations
- Heidelberg University (DE)
- University of Bonn (DE)
- Corresponding author
- Spanagel, Rainer
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2021-11-13
- Volume
- 47
- Issue
- 4
- Pages
- 832-839
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- PMC
- PMC8882178
- OpenAlex
- W3212471105
- Cited by
- 36
- References
- 68
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 8 · 2023: 7 · 2022: 5
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Neuropsychopharmacology (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- Bundesministerium für Bildung und Forschung (031L0190A, 01ZX01909)
- Deutsche Forschungsgemeinschaft (402170461)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- alcoholism, DNA methylation, epigenetics, brain regions, caudate nucleus, ventral striatum, anterior cingulate cortex, Brodmann area 9, putamen, postmortem brain, immune pathways, differentially methylated CpG sites
- MeSH terms
- Epigenome, Alcohol Drinking, Alcoholism, Brain, Humans, DNA Methylation, Epigenesis, Genetic, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review